Trial Profile

A phase 2a clinical trial of ETH 47

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2025 According to an Ethris GmbH media release,Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025.
19 Jun 2024 New trial record
18 Jun 2024 According to an Ethris GmbH media release, company has received funding from the Gates Foundation to support the advancement of ETH47. This funding of $5 million will enable the company to rapidly reach Phase 2 readiness and build out the CMC manufacturing process for the next clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com